Redeye views the news from Moberg Pharma that they have submitted an additional Terbinafine supplier...
Finnair reports Q1 results on Apr 23. Q1 is always seasonally soft and so the summer months are to d...
Redeye offers a preview of Advenica's Q1 results set to be released on April 25th.
Redeye has provided a brief comment on today's news regarding Acarix's submission of an application ...
Redeye comments on today’s news. Scibase has resolved a directed issue of c SEK 33m and a rights iss...
Binero announced cost savings measures with an expected SEK15m effect on EBIT from the fourth quarte...
Cardeon är ett investmentbolag som investerar i bolag inom life science i tidig fas.
Har ni glömt bort SinterCast? Traton och Volvo har rusat på börsen.
Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were ...
Redeye adjusts the Fair value range and Base case after the outcome of the rights issue has been con...
Core objectives, including divestments and securing bond refinancing completed One new divestment an...
Train Alliance förvärvar mark som är strategiskt utvald för järnvägsändamål.
Duell’s Q2 net sales came in at EUR 28.2m, above our estimate of EUR 25.
Redeye had a conversation with the founders of Strax after the latest divestments of Clickr to Matte...
Redeye takes a positive stance towards Avensia’s ambitious yet reasonable financial targets.
Redeye is optimistic about the new agreement with MSD/Merck to provide Keytruda for the combination ...
Ökat fotfäste i marknaden Nettoomsättningen i kvartalet visade att bolaget ökade fotfästet i marknad...
Redeye views today's press release from Lifecare positively, announcing that it has reached the targ...
Redeye comments on events in the fourth quarter report, including progress with bacterial vaccine pr...
Redeye retains its Base Case despite cutting its short-term EBIT forecasts slightly.
